---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011178"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:11:50.422061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tivic Health FY2022 revenue $1.8M (+46% YoY); cash $3.5M, no debt

## Summary
- Revenue $1.8M (+46% YoY); direct-to-consumer sales $1.6M (+114%).
- Gross profit $299K vs gross loss of $38K in 2021; 9X gross margin improvement.
- Operating expenses: R&D $1.7M, S&M $2.8M, G&A $5.9M (total $10.4M).
- Cash $3.5M, no debt; used for operations and attempted acquisition of Reliefband.
- CEO cites supply chain challenges but expects growth in 2023.

## SEC filing metadata
- accession: 0000950170-23-011178
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017023011178/0000950170-23-011178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017023011178/tivc-20230331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011178
- JSON: https://secwatch.observer/filing/0000950170-23-011178.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011178.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported the year ending December 31, 2022 results: revenue $1.8 million.
  - Period: the year ending December 31, 2022
  - Revenue: $1.8 million
  - Result: reported results
  source text: increased $583 thousand (46%) to $1.8 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023011178/0000950170-23-011178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.